Epstein-Barr virus (EBV)-immortalized human B cells sur-
vive only transiently when injected subcutaneously into athymic mice, whereas Burkitt's lymphoma cells give rise to progressively growing subcutaneous tumors.
In this study, we tested whether these Burkitt's tumors could be induced to regress via a bystander effect induced by EBVimmortalized B cells. Simultaneous inoculation of EBV-immortalized B cells and Burkitt's lymphoma cells in the same subcutaneous site resulted in tumors that regressed with necrosis and scarring. Similarly, simultaneous inoculation of EBV-immortalized B cells and Burkitt's lymphoma cells in separate subcutaneous sites resulted in regression DMINISTRATION of lymphocytes or tumor cells transduced with specific cytokine genes represent novel approaches for the treatment of cancer. By either providing antitumor effector cells or stimulating antitumor immunity at the tumor site, these experimental modalities have resulted in decreased tumorigenicity and regression of existing tumors in a number of experimental model^."^ Recently, retroviral-mediated transfer in vivo of a herpes-virus-derived thymidine kinase (tk) gene into a proportion of brain glioma tumor cells rendered them sensitive to destruction by an antiviral drug. It also led to death of other tumor cells, not transduced with the tk gene, through a poorly defined bystander effect." Despite these experimental results, the targeting of effector lymphocytes as well as anticancer cytokines and drug sensitivity factors to particular tumor sites has had limited clinical applications because it involves relatively complex procedures not widely available.' I We considered the possibility that tumor cell killing might be induced by inoculation of the tumor-bearing host with benign cells that are normally destroyed if inoculated into the same host. We reasoned that, by stimulating a local cytotoxic response in vivo, one might achieve killing of tumor cells through a bystander effect."
When injected subcutaneously into irradiated athymic (nude) mice, human B cells immortalized with Epstein-Barr virus (EBV) either fail to grow or give rise to small tumors that soon regress through necrosis and scarring.** The mechanism for this regression is not fully understood but has been attributed to residual host i m m~n i t y . '~ In the same experimental system, human Burkitt's lymphoma cells generally develop into lethal malignant tumors.I4
In the present study, we examined whether inoculation of EBV-immortalized B cells might have an antitumor effect against experimental Burkitt's lymphoma in athymic mice.
MATERIALS AND METHODS
Cells and cell lines. EBV-immortalized cell lines were obtained either by exposure of normal peripheral blood B cells to EBV (B95--8 strain) or by spontaneous outgrowth in vitro of peripheral blood B cells from normal EBV-seropositive individual^.'^ The Burkitt's lymphoma cell lines CA46 and JD38 were derived by spontaneous in vitro outgrowth of single cell suspended Burkitt's lymphoma tissues. l 6 All cell lines were maintained in RPMl I640 medium (Biofluids, Rockville, MD) supplemented with 10% heat-inactivated fetal calf serum (FCS; Reheis, Armour Pharmaceuticals, Kankakee, IL), 2 mmol/L L-glutamine (GIBCO, Grand Island, NY), and 5 ppl mL gentamicin (Sigma Chemical CO, St Louis, MO). All cell lines were mycoplasma-free. Peripheral blood T cells were obtained from normal mononuclear cells by rosetting with 2-aminoethylisothiouroniumbromide-treated sheep red blood cells. '5 Animal studies. Six-to eight-week-old female BALB/c nu/nu mice (National Cancer Institute [NCI], Bethesda, MD) maintained in pathogen-limited conditions were used throughout. Twenty-four hours before initiation of the experiments, the mice received 400-rad total body irradiation. Exponentially growing human B cell lines with a viability greater than 95% were injected ( lo7 cells in 0.2 mL RPMl 1640 medium containing 10% FCS) subcutaneously in the right abdominal quadrant through a 25-gauge needle on plastic l -mL syringes. In a number of experiments, two different cell lines were coinjected subcutaneously in the right abdominal quadrant (IO' cells from each of the cell lines in 0. I mL RPMI 1640 medium containing 10% FCS, total injection volume 0.2 mL). In some experiments, two different cell lines were simultaneously injected in distinct subcutaneous sites. the right and the left abdominal quadrant ( lo7 cells from each cell line in 0.2 mL RPMI 1640 medium containing 10% FCS). lntratumor injections were performed by inoculation of IO' cells suspended in 0.1 to 0.2 mL RPMI 1640 medium with 10% FCS into one site in the center of the tumor mass. All animals were observed twice weekly and tumor size was estimated in square millimeters as the product of two-dimensional caliper measurements (longest perpendicular length and width).
Reagents. Recombinant murine tumor necrosis factor-a (TNFa ) was a kind gift of Genentech, Inc (South San Francisco, CA); recombinant human interleukin-6 (IL-6) was a kind gift of Sandoz Pharmaceutical (Basel, Switzerland); lipopolysaccharide (LPS) 
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from Escherichia coli 0127:B8 was purchased from Sigma; a purified rabbit antiserum to highly purified natural murine IL-6" was a gift of Dr R. Nordan (NCI); a purified rabbit antiserum to recombinant murine TNF-a18 was a gift of Dr J. Weber (NCI).
Expression ofslrrfacedeterminants andofEB Vgenes. Exponentially growing human B cell lines and murine splenocytes ( IO7 cells/ mL in phosphate-buffered saline [PBS] containing 5% FCS) were incubated for 30 minutes at 4°C with control reagents or monoclonal antibodies (MoAbs). These included the murine antihuman MoAbs anti-CD23 (anti-Leu 2 0 Becton Dickinson Immunocytometry Systems, San Jose, CA), anti-CD10 (J5: Coulter Electronics, Inc, Hialeah, FL), anti-CD1 8 (CLB-CD18; Janssen Biochimica, Beerse, Belgium), anti-CD20 (anti-Leu 16; Becton Dickinson), and antitransfemn receptor (Becton Dickinson); the antimurine rat MoAbs Thy I .2 (clone 30-H 12) and CD45R (clone RA3-6B2), both from Pharmingen (San Diego, CA). When appropriate, the cells were further incubated (30 minutes at 4'C) with an affinity purified, fluorescein-labeled, goat antimouse reagent (Becton Dickinson). After washing, the cells were analyzed on an FACScan (Becton Dickinson). For each determination, IO4 cells were examined.
The EBV-encoded nuclear proteins EBNAI and EBNA2 were detected by Western blotting of cell lysates, using a human serum with high antibody titers to these antigens, as described."
Cell cultures. Splenocytes from 6-to 8-week old female BALB/ c nu/nu mice were incubated for 5 days (2 X lo6 cells/mL in 24-well tissue culture plates (Limbro; Flow Laboratories, Inc, McLean, VA) in complete mouse cell culture medium consisting of a 1: 1 mixture of RPMI-1640 medium (GIBCO) and enriched Eagle's medium (Biofluids, Inc, Rockville, MD) supplemented with 10% FCS (Reheis) 2 mmol/L L-glutamine (GIBCO), mol/L 2-mercaptoethanol (GIBCO), 5 pg/mLgentamicin (Sigma), and IL-2 (500 U/mL: a gift of Cetus Corp. Emeryville, CA), as described." Tumors were fragmented into single cell suspensions and cultured (2 X IO6 cells/ mL in 24-well tissue culture plates) in complete mouse cell culture medium.
Assaysfor IL-6, TNF, and interferon (IFN) bioactivities. The murine hybridoma cell line B9 (a gift of Dr R. Nordan, National Institutes of Health, Bethesda, MD) was used in a standard assay for IL-6 bioactivity.2' One unit of IL-6 bioactivity in this assay is defined as the activity inducing half-maximal proliferation of B9 cells. An IL-6 concentration of I U/mL corresponds to approximately 20 pg of E. coli-derived human IL-6 used throughout as a laboratory standard (a gift of Sandoz Pharmaceuticals). Murine IL-6 was identified by neutralization assays with a purified rabbit antiserum to highly purified natural murine IL-6I7 (agift of Dr R. Nordan, NCI). The fibroblast murine cell line L92 1 (a gift of Dr T. Gerrard, Center for Biologics Evaluation and Research) was used in a standard assay for TNF bioactivity. 22 One unit of TNF bioactivity in this assay is defined as the activity inducing one-half maximal lysis of L921 targets. A TNF concentration of I U/mL corresponds to approximately 100 pg of a recombinant human TNF-a preparation (a gift ofGenentech, Inc). Murine TNF-a was identified by neutralization assays with a purified rabbit antimurine TNF-a antiserum (rabbit IgG antirecombinant murine TNF-a; a gift of Dr J. Weber, NCI).I8 At the concentration of 20 &mL, this antiserum neutralized approximately 50 ng/mL recombinant murine TNF-a, as determined in the L92 I bioassay.
Murine and human interferon (IFN)-induced antiviral activity were quantified by cytopathic effect neutralization assays, as previously described. 22 The murine fibroblast L929 cell line was used for measuring murine I F N activity, and the human epithelial amnion cell line WISH (American Type Culture Collection [ATCC], Rockville, MD) was used for human I F N testing. One unit of I F N is defined as the reciprocal of the dilution that inhibits viral replication by 50%. Murine and human I F N reference standards were obtained from the NIH.
Cellprol~Jcration and cytoto.\-icily assa~?r. Cell proliferation was measured essentially as described.20 The Burkitt's lymphoma cell lines JD38 and CA46 in exponential growth phase were washed and cultured in triplicate at varying cell densities (250 to 2,000 cells/ well, in 96-well flat bottom plates: Costar), with or without recombinant murine TNF-(U ( I to 100 pg/mL), in RPM1 1640 medium containing 2 mmol/L L-glutamine (GIBCO), 5 pg/mL gentamicin (Sigma), and 10% FCS (Reheis). After 3 and 7 days of incubation, the cultures were pulsed with 'H-thymidine (0.5 &/well; New England Nuclear, Boston, MA) during 4.5 hours. Results were expressed as mean cpm * SD.
Cytotoxicity was measured using a 4.5-hour chromium release assay, as described." Briefly, murine leukemia YAC-1 cells (ATCC) as well as the Burkitt's and EBV-immortalized B-cell lines, described above, in exponential growth phase were used as 5'C-labeled targets. Fresh or IL-2-activated murine splenocytes were used as effectors at varying concentrations. The percent specific cytotoxicity was calculated as: 100 X ([experimental release -spontaneous release]/[total release -spontaneous release]).
Histology evullrution. Representative samples of tumor tissue were fixed in IO% neutral buffered-formalin (Media Kitchen: NIH), blocked in paraffin, sectioned at 4 r m , and stained with hematoxylin and eosin. Six 8-week-old female BALB/c nu/nu mice (NCI) maintained in pathogen-limited conditions were total body irradiated with 400 rad and, 2 4 hours later, were injected subcutaneously with 1 O7 cells (in 0.2 mL RPM1 1640 containing 10% FCS) from one of three B-cell lines or with mixtures of 1 O7 cells from each of two cell lines. B-cell lines used were VDS, obtained by EBV (895-8 strain) immortalization of normal B cells, as well as JD38 and CA46, EBV-negative Burkitt's lymphoma lines. The animals were observed twice weekly and tumor size was estimated in square centimeters as the product of two-dimensional caliper measurements (longest perpendicular length and width). Tumors were considered in regression either when two consecutive tumor measurements separated by 1 week showed a size reduction of at least 0.04 cm2 or when tumors developed superficial ulcers and scarring (at least 0.25 mm2 in size), indicative of tumor necrosis, without size increase.
RESULTS

In initial studies (
Abbreviation: LCL, lymphoblastoid cell lines (EBV-immortalized B-cell lines).
Five of these mice were killed during regression for in vitro studies.
immortalized VDS cells contralateral to the Burkitt's lymphoma JD38 cells was associated with Burkitt's tumor development in only 7 of 15 injected mice. Of these 7 JD38 tumors, 4 underwent regression that was complete in 3 cases. In control experiments, all 7 tumors occurring in animals injected with mixtures of VDS and JD38 cells in the same subcutaneous site resulted in tumor regression, and all 4 tumors resulting from injection of JD38 cells alone progressively grew. Thus, EBV-immortalized B cells can exert antitumor effect at some distance, although perhaps at reduced levels. Subsequently, we tested whether direct in situ injection of a growing Burkitt's lymphoma with EBV-immortalized B cells might be able to cause regression of an already established tumor (Table 3) In additional experiments (Table 4) , we found that biweekly injections of established JD38 or CA46 Burkitt's tumors with irradiated (1 5,000 rad, a dose resulting in 100% cell death after 1 week in culture) EBV-immortalized B cells (VDS, AVM, and FR lines) caused 13 of 17 tumors to regress. These experiments show that progressively growing Burkitt's tumors can be induced to regress by intratumor injection of EBV-immortalized B cells, even if the EBV-infected B cells are growth-inhibited and expected to die because of irradiation.
Microscopic examination of regressing tumors ( 10 examined) showed massive central necrosis extending to the epidermis, surrounded by viable lymphoid cells of medium and large size with prominent nucleoli. Infiltration with some histiocytes was seen within and at the periphery ofthe tumor (Fig 1) .
To elucidate the mechanism that mediates Burkitt's lymphoma regression in this experimental system, we first ex- athymic irradiated (400 rad) BALB/c mice (not shown). In addition, consistent with the absence of EBV in the injected cells, 2 regressing JD38 and CA46 tumors did not express detectable EBNAl and EBNA2 (not shown), viral nuclear proteins indicative of EBV infection." These findings indicated that Burkitt's cells from regressing tumors have not converted to a lymphoblastoid, nontumorigenic phenotype.
In additional experiments, we addressed the possibility that tumor regression might be caused by a host response to the EBV-infected cells, a response not elicited by the Burkitt's cells. Although T-cell immunity was unlikely to play a significant role here because we used young nude (athymic) mice known to have a profound defect in their T-cell immunit^,'^ we tested for the presence of T cells in mice with regressing tumors. In contrast to splenocytes of a normal adult BALB/c mouse that contained 47% Thy 1.2 positive cells, splenocytes from 2 nude mice bearing regressing tumors (JD38 X VDS) contained less than 1% cells positive for the Thy 1.2 antigen, a T-cell marker, indicating that no extrathymic T-cell had been induced by the subcutaneously injected human B-cell lines. Furthermore, IL-2-responsive cells could not be grown from 3 distinct regressing tumors. Both findings suggested that T-cell immunity was not responsible for tumor regression in this system. Nude mice are known to display high levels of natural killer (NK) functions.34 However, NK and lymphokine-activated killer (LAK) functions are unlikely to play a role in the present system, because Burkitt's cells are generally resistant to T-cell killing. 35, 36 We found that the Burkitt's cell line CA46 was not significantly killed (<l% killing at an effector to target ratio of 100: 1) by murine splenocytes from 3 separate nude mice that were either fresh or activated in vitro by culture with 500 U/mL IL-2. In control experiments, the IL-2-activated nude murine splenocytes displayed effective killing of YAC cells that are exquisitely sensitive to NK functions (46% to 97% killing at an effectorto-target ratio of lO0:l). Furthermore, splenocytes from 3 separate nude mice bearing regressing tumors were not more cytotoxic of YAC cell targets than were splenocytes from 3 nontumor-bearing control mice when tested fresh and even after IL-2 activation in vitro. At an effector to target ratio of 100: 1, the IL-2-activated splenocytes from control mice showed a mean killing of 68.3%, and those from tumor-bearing mice showed a mean killing of 5 1.7%.
Together, these findings indicated that NK and LAK cells are unlikely to mediate Burkitt's tumor regression in this experimental system. When separated into single cells and cultured in vitro, regressing Burkitt's tumors (presumably composed of human Burkitt's cells, human EBV-immortalized cells, and murine-reactive cells infiltrating the tumor) secreted significantly higher levels of murine IL-6 and TNF than did progressive Burkitt's tumors. None secreted detectable levels of murine IFN activity (Fig 2) . These findings suggested that EBV-immortalized B cells are more potent inducers ofthese cytokines than are Burkitt's cells in this experimental model. Murine IL-6 and TNF are unlikely to directly kill the human Burkitt's cells in vivo. Murine IL-6 does not bind to human IL-6 Recombinant murine TNF-a, known to act on a variety of human cells,38 neither significantly inhibited growth nor killed JD38 and CA46 cells in vitro (data not shown). However, we considered the possibility that TNF might have an indirect antitumor effect and tested whether recombinant TNF-a might induce Burkitt's tumor regression in this experimental system. To this end, 6 female irradiated BALB/c nu/nu mice were injected subcutaneously with IO7 cells from the JD38 cell line. When a subcutaneous tumor of at least 0.25 cm2 had developed, the mice were inoculated intratumorally with recombinant murine TNF-a (5 pg in 100 pL PBS). The TNF-a administra- VDS (1) Medium (1) VDS (1) TB (1) Medium (3) VDS (4) Medium (3) VDS (3) 1 .o VDS or TB cells (in 0.2 mL medium). The mice were injected once in experiments 1 through 3. In experiments 4 and 5, the mice were injected weekly until there was evidence of tumor regression or uncontrolled tumor progression. Animal and tumor evaluation was performed as described in the legend to Table l . Days to regression were calculated from the day of inoculation of the EBV-immortalized B cells.
tion was repeated after 5 days. Five of six established Burkitt's tumors underwent macroscopic hemorrhagic necrosis 24 to 48 hours after each inoculation with TNF-a. However, no tumor regression was complete, and all tumors eventually grew progressively. Recombinant human IL-6 inoculated alone intratumorally into 4 Burkitt's tumor-bearing athymic mice ( 15 p g in 100 pL PBS repeated after 5 days) had no effect on tumor growth; IL-6 also had no additive or synergistic effect when administered at this dose together with TNF (5 pg repeated after 5 days). These results suggested that murine TNF-a can induce Burkitt's tumors to regress in the present model system, even though the tumoricidal effect was transient under the conditions that we used. To further test for the possibility that TNF produced endogenously at the tumor site might be responsible for tumor regression in the present experimental system, we examined whether a neutralizing antibody to murine TNF-a might prevent or delay tumor regression. Thus, 5 8-week-old female BALB/c nu/nu mice were irradiated with 400 rad and, 24 hours later, were injected subcutaneously with IO' Burkitt's lymphoma JD38 cells in 0.2 mL culture medium. After having developed a subcutaneous mass (0.25 to 0.5 cmz Six 8-week-old female nu/nu BALB/c mice that developed a subcutaneous Burkitt's lymphoma, induced as described previously. were injected intratumorally twice weekly with either culture medium (0.2 mL) or with 10' EBV-immortalized cells from one of three B-cell lines (VDS, AVM, and FR) that were either untreated or irradiated with 15,000 rad before inoculation (injection volume, 0.2 mL). Animals and tumors were evaluated as described above.
* Days to regression were evaluated from the day of inoculation of the EBV-immortalized 8 cells.
For 2 :
x - nity. This difference in the natural history of Burkitt's and EBV-immortalized B-cell lines injected subcutaneously into athymic mice prompted us to test whether a host response elicited by the EBV-immortalized cells might result in Burkitt's tumor regression. When EBV-immortalized and Burkitt's lymphoma cells were simultaneously injected in the same subcutaneous site of irradiated young athymic mice, the resulting tumors uniformly regressed. Similarly, tumor regressions were observed when the EBV-immortalized and the Burkitt's cells were injected into separate subcutaneous sites, suggestive of a systemic effect. More importantly, treatment of established subcutaneous Burkitt's tumors with EBV-immortalized cells injected into the tumor almost always resulted in tumor regression. Furthermore, the EBVimmortalized cells continued to exert an antitumor effect, even after exposure to lethal doses of irradiation. Together, these experiments show that EBV-immortalized cells can exert an effective antitumor activity against experimental Burkitt's tumors in athymic mice.
-
Burkitt's tumor regression in this model system followed characteristic patterns. The tumors first developed a central scar that progressively enlarged to cover the entire tumor mass. Subsequently, the scar fell off, and new skin formed. Occasionally, small tumors regressed by progressive size reduction, without superficial scarring. Histologically, tumors with macroscopic evidence of regression showed central necrosis extending to the epidermis and variable numbers of surrounding viable-looking cells of medium to large size with prominent nucleoli. Tumor infiltration with inflammatory cells was not prominent and consisted of histiocytes both within and at the periphery of the regressing tumors.
The mechanism that mediates Burkitt's lymphoma regression in this system has not been fully elucidated. However, several mechanisms were examined in detail. Initially, we considered the possibility that the EBV-immortalized cells induce the Burkitt's cells to switch to a less tumorigenic, lymphoblastoid p h e n~t y p e .~~-'~ However, Burkitt's cells rescued from regressing tumors were indistinguishable from Burkitt's cells maintained in vitro in the expression of those surface markers that are known to distinguish a lymphoblastoid from a Burkitt's phen~type.'~-*~ They also continued to be EBV-negative and to be highly tumorigenic in athymic mice. These findings suggested that tumor regression was more likely caused by stimulation of a tumoricidal response in this host.
Although severely immunocompromised, nude mice display high levels of NK function34 and may develop activated monocytes in response to certain tumor cells.39 In addition, athymic mice may develop mature murine T cells after inoculation of human T cells, presumably because of extrathymic precursor T-cell mat~ration.~'"~ We looked for the presence of mature T cells in the spleens of nude mice with regressing Burkitt's tumors, but found them to be less than 1% of the splenocytes. T cells also appeared to be absent at the tumor site, because we were unable to grow IL-2-responsive cells from regressing tumors. Furthermore, subcutaneous inoculation of Burkitt's lymphoma cells into 2 nude mice that had previously rejected the same Burkitt's For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
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tumor after intratumor injections with EBV-immortalized cells resulted in the appearance of progressively growing tumors (preliminary results not shown). This suggests that tumor regression in this system is not associated with T-cell memory.
In subsequent experiments, we explored the role of NK cells in Burkitt's tumor regression. However, we found that one of the Burkitt's cell lines used here, CA46, was highly resistant to killing from fresh nude splenocytes. This cell line was also resistant to killing by IL-2-activated nude splenocytes. In addition, mice with regressing Burkitt's tumors did not show increased splenocyte killing of NK-sensitive targets. Thus, it appeared unlikely that either T cells or NK cells were involved in tumor regression in the present system.
Cell suspensions derived from regressing Burkitt's tumors were found to secrete significantly higher levels of murine IL-6 and TNF-a compared with those from progressive tumors. This suggested that EBV-immortalized cells are more potent inducers of inflammatory cytokines than are Burkitt's cells, and prompted us to examine whether IL-6 and/ or TNF-a might be involved in tumor regression. A direct effect of the murine cytokines on the human Burkitt's cells appeared unlikely because murine IL-6 does not bind to the human IL-6 re~eptor,~' and recombinant murine TNF-a neither inhibited the growth nor killed Burkitt's cells in vitro. However, TNF-a is known to cause intravascular thrombosis and, secondarily, tumor tissue All the regressing tumors studied here had central necrosis occasionally surrounding a blood vessel, suggesting that tumor necrosis may be related to tissue ischemia. In addition, we observed that 5 of 5 established Burkitt's tumors underwent macroscopic necrosis after 1 or 2 intratumor inoculations of 5 p g recombinant murine TNF-a. In contrast, IL-6 was ineffective alone and appeared not to increase the tumoricidal effect of exogenous TNF-a. Although the effects of exogenous TNF-a injection were transient, it was possible that endogenously produced TNF at the tumor site, over a prolonged period of time, might have been responsible for Burkitt's tumor regression. However, multiple intraperitoneal injections of a neutralizing antiserum to murine TNF-a failed to appreciably affect tumor regression. Although TNF may be one of several factors involved, a role for TNF in Burkitt's tumor regression induced by EBV-immortalized B cells remains uncertain.
As discussed above, initial necrosis characterizes tumor regression in this system, suggesting that tissue ischemia may be central to this process. We now believe that factors regulating vascular endothelium growth and survival at the tumor site may be responsible for Burkitt's lymphoma's progressive growth and regression in this system. Our present understanding ofthe intricacies of vascular endothelium biology is still limited, but this is an increasingly active area of investigation. Elucidation of these processes is essential for understanding Burkitt's tumor growth and regression in this system.
With improved chemotherapeutic and adjuvant therapies, Burkitt's lymphoma is cured in 70% to 80% of all case^.^',^^ However, B-cell lymphomas in acquired immunodeficiency syndrome, including Burkitt's lymphoma, have a median survival of 2.5 months despite the rap^.^' Although further study will be necessary to clarify the mechanisms for the observed antitumor effects, these data support the potential cIinical application of this approach for treatment of Burkitt's tumors not amendable to other treatments.
